INTRODUCTION
============

The burden of human Immunodeficiency Virus (HIV) infection in Nigeria is the second highest world-wide with a challenge to the public health.^[@R1]^ The prevalence of the disease is high among adolescents in sub-Saharan African countries.^[@R2],[@R3]^ In them, the disease might have been contacted from birth, or via unprotected sexual intercourse, use of contaminated blood products and practice of sharing sharp objects.^[@R4],[@R5],[@R6],[@R7]^

HIV-infection is a risk factor for hearing loss and the magnitude seems to increase with the severity of the disease.^[@R8]^ This may be conductive or sensorineural. The sensorineural hearing loss in HIV patients may be due to direct neurotropic effect of HIV on either the central ner vous system or peripheral auditory ner ve (neurotoxicity).^[@R9],[@R10],[@R11]^ Sudden sensorineural hearing loss and demyelination in the brain stem with significant increase in latencies on auditory brain stem has been reported ^[@R12],[@R13]^ and this may be due to the direct action of the virus on central nervous system. Other causes of hearing loss in HIV infected adolescent may include chronic suppurative otitis media, ototoxicity from antiretroviral therapy and aminoglycosides used in the treatment of tuberculosis which is a common opportunistic infection that is associated with HIV. ^[@R8],[@R14],[@R15]^

Meningitis and encephalitis may occur as an opportunistic infection in HIV patients because of poor humoral and cell-mediated immunity, with a significant consequence on hearing threshold.^[@R16]^ The defective chemotaxis and phagocytosis may cause increased vulnerability to middle ear infection^[@R17]^. The persistent generalized lymphadenopathy could block the Eustachian tube opening leading to serous otitis media and conductive hearing loss.

The value of CD4 cell count measures the degree of immunosuppression in HIV-positive patients. Highly active antiretroviral therapy (HAART) often leads to substantial reduction in viral load and immune recovery in HIV-infected individual.^[@R18]^ CD4 T-cell status is a strong prognostic indicator of mortality and disease progression among individuals living with HIV.^[@R19]^ Some antiretroviral medications may be ototoxic^[@R20]^, thus it has been difficult to make conclusions regarding the cause of changes in hearing function in HIV-infected patients on the medication.

Accelerated aging has been suggested as a potential explanation for the disproportionate increase in complications of age related problems including hearing loss even in individuals living with HIV/AIDS. Improved medical, nutritional, psychosocial and pharmacological care have converted HIV infection from a terminal to a chronic health condition with increased life expectancy^[@R8]^, thus making them to need long-term hearing care.

Information is sparse on hearing status of HIV-infected adolescents in Nigeria, hence this study was conducted to determine hearing threshold and the association between it and viral load, CD4 cell counts and HAART administration.

MATERIALS AND METHODS
=====================

This was a cross sectional study of HIV-infected adolescents at President\'s Emergency Plan For AIDS Relief (PEPFAR) clinic, University College Hospital, Ibadan, Nigeria. Ethical approval was obtained from the ethics committee of University of Ibadan/ University College Hospital, Ibadan for the conduct of the study. Participants with clinical history suggestive of risk factors for hearing loss were excluded from the study. Permission was also obtained from the management of the clinic, and Informed consent was obtained from their caregivers and assent was obtained from each participant. A convenient sampling method was done to recruit the participants.

Proforma
--------

was used to gather information/data on sex, age, tribe, religion, duration of HIV infection, sources of infection, use of HAART medications, ear symptoms, history of hearing impairment, and family history of hearing loss. Clinical and otoscopic examination of the ear was performed and findings documented. Those with ear-wax and debris had removal done before hearing test was performed.

Pure Tone Audiometry
--------------------

The procedure was clearly explained to the patients. In a quiet room, patients sat backing the equipment and signified hearing the tone by raising hand above the head level. Pure tones were delivered to each ear consecutively using ear phones to test for air-conduction (AC). The duration of presentation was 2-3 seconds. The test was conducted firstly on the right ear at 250Hz, 500Hz, 1KHz, 2KHz, 4KHz, 6KHz and 8KHz. The test started by presenting pure tone at 40dBHL, if audible then was reduced in 10dB steps till no response occurred, thereafter it was increased by 5dB steps till a response occurred and the result plotted. If no response occurred at 80dBHL, then it was increased by 5dB steps until a response occurred. The left ear was then tested in similar manner. A pure tone average was calculated at the speech frequencies 500Hz to 4 KHz. To test for bone conduction (BC), the bone vibrator was placed on the mastoid of the test ear (the worse ear on AC) delivering different tones at each of the speech frequencies from 500Hz to 4000Hz. Sensorineural hearing loss (SNHL) was diagnosed when the air and bone conduction thresholds on audiogram were within 10dB of each other and thresholds were higher than 25dBHL. Mixed hearing loss (MHL) was diagnosed when the air conduction thresholds were poorer than bone conduction thresholds by more than 10dB, and bone conduction thresholds were less than 25dB.

Conductive hearing loss (CHL) was diagnosed if the bone conduction thresholds were less than 25dB while the air conduction thresholds are higher than 25dB. In this study, hearing was said to be normal if hearing threshold is less than 26 dB HL. Hearing impairment was classified as Mild (26 to 40 dB HL), Moderate (41 to 55 dB HL), Moderately severe (56 to 70 dBHL), Severe (71 to 90 dB HL), Profound (91 dBHL and above).^[@R21]^

In this study, disabling hearing loss is defined as permanent unaided hearing threshold level in the better ear of 31 dB or greater\" in the better hearing ear for participants under the age of 15 years and 40dB or greater in older people.^[@R22]^

Statistical analysis:
---------------------

Data collected were inputted into Statistical Products and Service Solutions (IBMSPSS version 20). Data analysis was done by univariate analysis and multivariate logistic regression where applicable. Some results were presented in tables and charts where appropriate. The mean and standard deviations were computed for all quantitative variables. Level of statistical significance was set at P \< 0.05.

RESULT
======

There were 63 participants comprising of 26 (41.3%) males and 37 (58.7%) females. Their ages ranged from 13 - 17 years. Thirty-two (50.8%) belonged to the low socioeconomic class, 18(28.8%) belonged to the. middle socioeconomic class and 13 (20.6%) belonged to the high socioeconomic class. All the participants were on daily dosage of co-trimoxazole and highly active antiretroviral therapy (HAART) with 41 (65.1%) participants on Lamivudine+Zidovudine+ Nevirapine and 22 (34.9%) participants on Lamivudine +Zidovudine+Efavirez. The period of HAART usage ranged from 10 months to 9 years (mean of 6.9 ± 3.7years). There was no association between duration of HAART usage and the degree of hearing loss (p=0.81) as shown in Table [1](#T1){ref-type="table"}. Hearing loss in the better ear was found in 13 (20.6%) participants, which was mild in 12 (92.3%) participants and moderate in one participant. The type of hearing loss was sensorineural hearing loss in 11 (84.6 %) and mixed hearing loss in 1 (7.7%) participant.

Of the participants with hearing loss, 8 (61.5%) had disabling hearing loss. The hearing loss has no association with age (p = 0.2). Hearing loss occurred among patients treated with each of the HAART regimens, but there is no association between hearing loss and the HAART - regimen, after excluding the confounding factors like age, gender and duration of usage of the HAART (p = 0.11). The Nadir viral load of the participants ranged from 29,653 - 76,983 copies/ml, mean of 54,711 ± 11,876 copies/ml while latest viral load ranged from 201 - 4,500 copies/ml, mean of 413 ± 287 copies/ml. The hearing thresholds is associated with nadir viral load (p= 0.03), but not the latest viral load (p = 0.18).

The Nadir CD4 cell count of the participants ranged from 227 - 365 cells/mm3, mean of 301.83 ± 28.11 cells/mm 3 while the latest CD4 cell count ranged from 487 cells /mm3 to 1,264 cells/mm3, mean 512 ± 101 cells/mm3. The hearing threshold is associated with the nadir CD4 cell count (p = 0.03), but not with latest CD4 cell count (p = 0.35) as shown in table [2](#T2){ref-type="table"}. Multiple logistic regressions showed that nadir viral load and nadir CD4 cell count could be associated with hearing loss.

DISCUSSION
==========

The participants\' age falls within the age group of adolescents with HIV- infection in the previous reports.^[@R23]^ The prevalence of hearing impairment in this study is higher than the prevalence of hearing loss among children in the general population^[@R24]^, and lower than the prevalence of 38.8% among HIV infected children in Peru.^[@R25]^ This difference may be due to environmental factors, viral load and CD4 cell count status of the participants.

Although, conductive HL is the principal type of hearing loss in HIV infection,^[@R15],[@R16],[@R26]^ sensorineural hearing loss was predominant in this study. The direct effect of HIV virus on the central nervous system or peripheral auditory nerve might have contributed.^[@R26]^ The low incidence of conductive hearing loss in our study may be because none of the participants had history of ear discharge.^[@R26]^ This difference may also be due to age of children investigated as this present study only investigated the hearing of adolescents. Studies have shown the cause of conductive hearing loss in HIV infected to be Eustachian tube dysfunction and depressed cell mediated immunity, which markedly increase susceptibility to middle ear infection.^[@R27]^ The Eustachian tube dysfunction in HIV adolescents may be due to nasopharyngeal lymphoid hyperplasia, sinusitis, allergies and their associated mucosal changes that results in obstruction of the Eustachian tube and impairs the middle ear ventilation.^[@R28]^

Torre et al ^[@R29]^ reported HIV as a factor for hearing loss, and the magnitude of hearing loss seems to increase with the severity of HIV. The association of hearing loss with the nadir viral load and CD4 count in this study supports the notion that high level of HIV virus and low CD4 count may contribute to worsening hearing. Although, mild hearing loss was found in majority of the adolescent, this has been reported to affect school performance and social interaction. In this study, there was no relationship between hearing loss and HAART. Early initiation of antiretroviral therapy may prevent hearing loss as there are no consensus that antiretroviral medications could affect hearing. If care of these hearing impaired adolescent is neglected, it could affect their communication, social and educational development, with significant consequences on the communities and the country.^[@R30]^ Hearing loss increased with increasing age among the participants, though not statistically significant, probably because the participants were within the same age bracket. The observed none association between hearing thresholds, and latest CD4 cell count and viral load of the participants supports the neurotoxic aetiopathogenesis effect of HIV on the auditory system. The introduction of the HAART reduced the viral load and improved their CD4 cell counts as shown in Table [1](#T1){ref-type="table"}. Low CD4 count has been reportedly associated with neural degeneration in HIV-infected individuals.^[@R31]^

Limitation
==========

of this study is that it is a cross sectional study, the audiological profile were not monitored routinely in the clinic while patients were on the HARRT regimen

###### 

Demographic and laboratory parameters of the participants

                                        Hearing loss in the better ear                  
  ------------------------------------- -------------------------------- -------------- ------
  **Sex**                                                                               
    Male                                6(9.5%)                          23(36.5%)      
    Female                              7(11.1%)                         27(42.9%)      0.45
  **Mean age**                          14 ± 2.2                         13 ± 2.8       0.35
  **Viral load (copies/ml)**                                                            
    Nadir                               28,611 ± 419                     27,222 ± 433   0.03
    Latest                              415 ± 22.7                       398 ± 25.7     0.35
  CD4 cell count cells/mm3                                                              
    Nadir                               292.8± 98.3                      362 ± 27.1     0.03
    Latest                              499 ± 12.6                       508 ± 11.5     0.18
  **Duration of HAART usage (years)**   6.7 ± 2.                         7.1 ± 3.5      0.10
  HAART regimen                                                                         
  **  I**                               9 (14.3%)                        32 (50.8%)     0.08
  **  II**                              4 (6.3%)                         18 (28.6%)     0.53

Note : Regimen I: Lamimudine+Zidovudine+Nevirapine;

Regimen II: Lamivudine+Zidovudine+Efavirez

###### 

Hearing threshold of the participants

  Factors                                                                       Disabling Hearing Loss              
  ---------------------------------------- ------------------------------------ ------------------------ ---------- -------------
  Gender                                   Male                                 5(38.4%)                 3(23.1%)   8(61.5%)
  Female                                   3(23.1%))                            2(15.3%)                 5(38.4%)   
  Degree of hearing loss                   Mild hearing loss (26 to 40 dB HL)   7(53.8%)                 5(38.5%)   12 (92.3%))
  Moderate hearing loss (41 to 55 dB HL)   1(7.7%)                              0(0%)                    1(7.7%)    
  Type of hearing loss                     Sensorineural Hearing Loss           6(46.1%)                 5(38.5%)   11 (84.6 %)
  Mixed Hearing Loss                       1(7.7%)                              0(0%)                    1(7.7%)    
  Conductive Hearing Loss                  1(7.7%)                              0(0%)                    1(7.7%)    
